These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38193274)

  • 1. Efficacy of dupilumab in palmoplantar pustulosis treatment highlights the role of Th2 inflammation.
    Zheng YX; Chen XB; Wang ZY; Cai SQ; Zheng M; Koh LF; Common JE; Man XY
    Allergy; 2024 May; 79(5):1361-1364. PubMed ID: 38193274
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis.
    Bertelsen T; Kragballe K; Johansen C; Iversen L
    Int J Dermatol; 2014 Oct; 53(10):e464-6. PubMed ID: 24962808
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report.
    Zheng YX; Zheng M; Cai SQ
    Dermatol Ther; 2022 Nov; 35(11):e15781. PubMed ID: 35986706
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of palmoplantar pustulosis with ustekinumab--the importance of interfering with the IL23/Th17 pathway.
    Pinto-Almeida T; Torres T; Sanches M; Selores M
    Eur J Dermatol; 2013; 23(6):916-7. PubMed ID: 24280259
    [No Abstract]   [Full Text] [Related]  

  • 5. Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.
    Benzecry V; Pravettoni V; Segatto G; Marzano AV; Ferrucci S
    J Investig Allergol Clin Immunol; 2021 Jun; 31(3):261-263. PubMed ID: 32732182
    [No Abstract]   [Full Text] [Related]  

  • 6. Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy.
    Yang D; Huang T; Liu B; Du Z; Liu C
    J Asthma; 2020 Jan; 57(1):79-81. PubMed ID: 30821528
    [No Abstract]   [Full Text] [Related]  

  • 7. Local injection of micro-dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment.
    Zhou C; Chen D; Diao Z; Wang Y; Hou Y; Yin Z
    Australas J Dermatol; 2024 May; 65(3):e75-e76. PubMed ID: 38439213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spesolimab: Is it a new treatment target in palmoplantar pustulosis?
    Huang H; Zhang Y; Wu Y; Li C
    Int J Rheum Dis; 2024 May; 27(5):e15154. PubMed ID: 38720596
    [No Abstract]   [Full Text] [Related]  

  • 9. Guselkumab for the treatment of palmoplantar pustulosis.
    Murakami M
    Expert Opin Biol Ther; 2020 Aug; 20(8):841-852. PubMed ID: 32321322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab.
    Honma M; Nozaki H; Hayashi K; Iinuma S; Ishida-Yamamoto A
    J Dermatol; 2019 Dec; 46(12):e468-e469. PubMed ID: 31502309
    [No Abstract]   [Full Text] [Related]  

  • 11. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.
    Sadik CD; Thieme M; Zillikens D; Terheyden P
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e406-e407. PubMed ID: 31131924
    [No Abstract]   [Full Text] [Related]  

  • 12. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
    Huang IH; Wu PC; Chiu HY; Huang YH
    Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Indications of Dupilumab in Th-2 Inflammatory Disease.
    Ilaria P; Nevena S; Ersilia T; Nicoletta B; Federica T; Di Fraia M; Agniezska D; Concetta P
    Rev Recent Clin Trials; 2024; 19(1):53-61. PubMed ID: 38141197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of Dupilumab in Prurigo Nodularis.
    Romano C
    J Investig Allergol Clin Immunol; 2021 Apr; 31(2):162-163. PubMed ID: 32573461
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of severely itchy scalp psoriasis and palmoplantar pustulosis with unsatisfied response to secukinumab, adalimumab or ustekinumab using upadacitinib: A report of two cases.
    Hu W; Wang Y; Zhang S; Wu X; Lian C
    J Dermatol; 2024 May; 51(5):e151-e153. PubMed ID: 38031884
    [No Abstract]   [Full Text] [Related]  

  • 16. Dupilumab treatment of nummular dermatitis: A retrospective cohort study.
    Choi S; Zhu GA; Lewis MA; Honari G; Chiou AS; Ko J; Chen JK
    J Am Acad Dermatol; 2020 May; 82(5):1252-1255. PubMed ID: 31923445
    [No Abstract]   [Full Text] [Related]  

  • 17. [Psoriasis in dupilumab-treated atopic dermatitis].
    Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
    Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for chronic palmoplantar pustulosis.
    Obeid G; Do G; Kirby L; Hughes C; Sbidian E; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011628. PubMed ID: 31958161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis.
    Jia X; Li C; Wu J; Liu Q
    J Drugs Dermatol; 2022 Mar; 21(3):311-312. PubMed ID: 35254760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis.
    Rueda-Gotor J; González-Gay MA; Blanco Alonso R; Gonzalez-Vela C; Lopez-Obregon C; González-López MA
    Joint Bone Spine; 2012 Oct; 79(5):510-3. PubMed ID: 22857979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.